Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Dec;17(18):2097-2114.
doi: 10.2217/pgs-2016-0116. Epub 2016 Nov 24.

Pharmacogenomics of second-line drugs used for treatment of unresponsive or relapsed osteosarcoma patients

Claudia M Hattinger  1 , Serena Vella  1 , Elisa Tavanti  1 , Marilù Fanelli  1 , Piero Picci  2 , Massimo Serra  1
Affiliations
Review

Pharmacogenomics of second-line drugs used for treatment of unresponsive or relapsed osteosarcoma patients

Claudia M Hattinger et al. Pharmacogenomics. 2016 Dec.

Abstract

Second-line treatment of high-grade osteosarcoma (HGOS) patients is based on different approaches and chemotherapy protocols, which are not yet standardized. Although several drugs have been used in HGOS second-line protocols, none of them has provided fully satisfactory results and the role of rescue chemotherapy is not well defined yet. This article focuses on the drugs that have most frequently been used for second-line treatment of HGOS, highlighting the present knowledge on their mechanisms of action and resistance and on gene polymorphisms with possible impact on treatment sensitivity or toxicity. In the near future, validation of the so far identified candidate genetic biomarkers may constitute the basis for tailoring treatment by taking the patients' genetic background into account.

Keywords: CYP450; adverse drug reactions; chemotherapy; drug resistance; drug transporter genes; osteosarcoma; pharmacogenomics.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure

The authors’ studies cited in this manuscript were supported by grants from the Italian Association for Cancer Research (Associazione Italiana per la Ricerca sul Cancro, A.I.R.C.; grants to M Serra) and Istituto Ortopedico Rizzoli (5x mille contributions to the Rizzoli Institute). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Rosenberg AE, Cleton-Jansen A-M, de Pinieux G, et al. Conventional osteosarcoma. In: Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F, editors. WHO classification of tumours of soft tissue and bone. IARC; Lyon: 2013. pp. 282–288.
    1. Picci P. Classic Osteosarcoma. In: Picci P, Manfrini M, Fabbri N, Gambarotti M, Vanel D, editors. Atlas of Musculoskeletal Tumors and Tumorlike Lesions. Springer International Publishing; Cham, Switzerland: 2014. pp. 147–152.
    1. Bruland OS, Pihl A. On the current management of osteosarcoma. A critical evaluation and a proposal for a modified treatment strategy. Eur. J. Cancer. 1997;33(11):1725–1731. - PubMed
    1. Ferrari S, Serra M. An update on chemotherapy for osteosarcoma. Expert Opin. Pharmacother. 2015;16(18):2727–2736. - PubMed
    1. Hattinger CM, Fanelli M, Tavanti E, et al. Advances in emerging drugs for osteosarcoma. Expert Opin. Emerg. Drugs. 2015:1–20. - PubMed

    2. • Interesting overview about the present and the future treatment approaches for high-grade osteosarcoma (HGOS).

MeSH terms

LinkOut - more resources